

Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article

As mentioned several times previously,¹⁻³ Thieme, the publisher of *Seminars in Thrombosis and Hemostasis*, has recently created the Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards in honor of Eberhard Mammen (Fig. 1) and in recognition of his contribution to this field and to the journal he both founded and steered for over three decades. Beginning in 2009, *Seminars in Thrombosis and Hemostasis* will thus begin a series of annual awards in recognition of excellence in the field of thrombosis and hemostasis. There are two categories of awards:

- Most popular article awards: Awards for the most popular articles published in *Seminars in Thrombosis and Hemostasis* using download data for the preceding 2 years. The awards comprise two major cash prizes of \$US1000, plus “open access” status for these articles thereafter. The editor-in-chief will determine the awards on the basis of download information provided by the publisher.
- Young investigator awards: Best presentation or meeting abstract by a young investigator, as presented or delivered to an international meeting on a topic related to the field of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of \$US1000 in any year, awarded for one or more presentations at each of three or more international meetings per year. The award winners will be expected to prepare a review or other related article on the topic of their presentation for publication in *Seminars in Thrombosis and Hemostasis*.

Further details of the awards and the award winners will also be posted online (<<http://www.thieme.com/journals/STHarticlewinners.html>>).

Accordingly, it is with great pleasure that we announce the winners of the inaugural Eberhard F.

Mammen award for the two most popular articles from *Seminars in Thrombosis and Hemostasis* for the period of 2007–2008 inclusive. Table 1 also identifies the top-25 downloaded articles⁴⁻²⁸ from this period.

The two most popular articles were by Girolami and Girolami (Fig. 2; “Heparin-Induced Thrombocytopenia”)⁴ and Jurk and Kehrel (Fig. 3; “Platelets: Physiology and Biochemistry”).⁵ Accordingly, we offer our congratulations to these 2009 Eberhard F. Mammen award winners. I must admit I was very pleased to see the article by Jurk and Kehrel⁵ awarded this prize. Published in 2005, this popular article was actually included in the top-20 most popular article listings in three separate years: 2005, 2006, and 2007.²⁹ An outstanding achievement indeed! The article by Girolami and Girolami,⁴ published in late 2006, was also the most popular one of 2007.²⁹

Interestingly, neither of these two articles was published within the data capture year of 2007 or 2008. Indeed, several articles within the top-25 listing (Table 1) were written years before 2007–2008. This likely relates to several factors, including (in addition to the popularity and the relative timeless nature of the topics) the fact that pre-2007 articles were available for downloading for the entire 2-year period of data capture. Nevertheless, there are several articles on this list that were published in 2007 and 2008, including another article on heparin-induced thrombocytopenia,⁸ plus several articles on current or emerging anticoagulants,^{9,10,16} and the perennial favorite “thrombophilia,” or thrombosis in its myriad incantations.^{6,11,12,14,15,17,19,21,25}

I was fortunate to catch up with both Beate E. Kehrel and Kerstin Jurk in Boston in July, during the most recent International Society on Thrombosis and Haemostasis (ISTH) congress. They expressed a hope to contribute further articles in the near future. Interestingly, the invitation for Beate Kehrel to write her article came personally from Eberhard while at an international meeting, and both Beate and Kerstin Jurk were very

¹Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, WSAHS, Westmead, Australia.

Address for correspondence and reprint requests: Emmanuel J. Favaloro, Ph.D., M.A.I.M.S., Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, WSAHS, Westmead, Australia.

Coagulopathies and Thrombosis: Usual and unusual causes and associations, Part II; Guest Editors, Giuseppe Lippi, M.D., Massimo Franchini, M.D., and Emmanuel J. Favaloro, Ph.D., M.A.I.M.S.

Semin Thromb Hemost 2009;35:587–590. Copyright © 2009 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

DOI 10.1055/s-0029-1242711. ISSN 0094-6176.



Figure 1 Eberhard F. Mammen (1930–2008).

happy to hear they had won this award. In Beate's own words, "Both of us love platelets and feel that we need to make scientists and medical doctors more familiar with the Cinderellas of the blood cells."

Antonio Girolami and Bruno Girolami are a father-and-son coauthorship team. They were unable to attend the Boston meeting. Interestingly, Antonio first became acquainted with Eberhard Mammen ~25 years ago at the meeting of the American Society of Hematology and met him several times subsequently at various international meetings. The invitation to write their article came from the guest editor for that issue of *Seminars in Thrombosis and Hemostasis* (Paolo Prandoni) in consultation with Eberhard.

Once again, we congratulate the inaugural Eberhard F. Mammen award winners, as well as all the authors who contributed to the articles in the top-25

Table 1 Top 25 Downloaded Articles from *Seminars in Thrombosis and Hemostasis* (2007–2008)

Ranking	Article
1	Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. 2006;32:803–809
2	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. 2005;31:381–392
3	Pini M, Spyropoulos AC. Prevention of venous thromboembolism. 2006;32:755–766
4	Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ Jr. Tumor lysis syndrome. 2007;33:397–407
5	Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. 2008;34:86–96
6	Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. 2008;34:39–57
7	Laux V, Perzborn E, Kubitz D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. 2007;33:515–523
8	Kucher N, Goldhaber SZ. Risk Stratification of acute pulmonary embolism. 2006;32:838–847
9	Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing. 2007;33:573–581
10	Esmon CT. Inflammation and the activated protein C anticoagulant pathway. 2006;32 (Suppl 1):49–60
11	Ho VT, Linden E, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. 2007;33:373–388
12	Agno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. 2006;32:651–658
13	Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahj R, Clarke M, Adiguzel C, Bick R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. 2008;34:58–73
14	Bernardi E, Pesavento R, Prandoni P. Upper extremity deep venous thrombosis. 2006;32:729–736
15	Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. 2007;33:350–354
16	Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. 2007;33:588–596
17	Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. 2006;32:307–340
18	Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. 2007;33:313–320
19	Siegel-Axel DI, Gawaz M. Platelets and endothelial cells. 2007;33:128–135
20	Stellos K, Gawaz M. Platelets and stromal cell-derived factor-1 in progenitor cell recruitment. 2007;33:159–164
21	Enjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. 2008;34:683–691
22	Middeldorp S, Levi M. Thrombophilia: an update. 2007;33:563–572
23	Zakarjija A, Bennett C. Drug-induced thrombotic microangiopathy. 2005;31:681–690
24	De Stefano V, Rossi E, Za T, Leone G. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. 2006;32:767–780
25	Davie EW, Kulman JD. An overview of the structure and function of thrombin. 2006;32 (Suppl 1):3–15



Figure 2 Bruno Girolami (left) and Antonio Girolami (right). Photo taken outside the Institute of Semeiotica Medica, Padua University.



Figure 3 Beate E. Kehrel (left) and Kerstin Jurk (right), with Emmanuel J. Favaloro (center). Photo taken in Boston in July 2009, during the most recent International Society on Thrombosis and Haemostasis (ISTH) congress.

listing. Your work has captured that extra level of attention from your scientific and clinical colleagues. For those contributors to *Seminars in Thrombosis and Hemostasis* who did not make the list this time, please don't despair. Your work still comprises a very important contribution to the journal, and we are all very grateful for your participation in *Seminars in Thrombosis and Hemostasis*.

I look forward to seeing the next listing in 2010!

Emmanuel J. Favaloro, Ph.D., M.A.I.M.S.¹
Editor in Chief

REFERENCES

1. Favaloro EJ. Editorial. Welcome to a special issue of *Seminars in Thrombosis and Hemostasis*—the closing issue for 2008. *Semin Thromb Hemost* 2008;34:693–696

2. Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930–2008). *Semin Thromb Hemost* 2008;34(8):703–707
3. Favaloro EJ. Editorial. Welcome to the first issue of *Seminars in Thrombosis and Hemostasis* for 2009. *Semin Thromb Hemost* 2009;35:1–2
4. Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. *Semin Thromb Hemost* 2006;32(8):803–809
5. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. *Semin Thromb Hemost* 2005;31(4):381–392
6. Pini M, Spyropoulos AC. Prevention of venous thromboembolism. *Semin Thromb Hemost* 2006;32(8):755–766
7. Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ Jr. Tumor lysis syndrome. *Semin Thromb Hemost* 2007;33(4):397–407
8. Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. *Semin Thromb Hemost* 2008;34(1):86–96
9. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. *Semin Thromb Hemost* 2008;34(1):39–57
10. Laux V, Perzborn E, Kubitzka D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. *Semin Thromb Hemost* 2007;33(5):515–523
11. Kucher N, Goldhaber SZ. Risk stratification of acute pulmonary embolism. *Semin Thromb Hemost* 2006;32:838–847
12. Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing. *Semin Thromb Hemost* 2007;33(6):573–581
13. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. *Semin Thromb Hemost* 2006;32(Suppl 1):49–60
14. Ho VT, Linden E, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. *Semin Thromb Hemost* 2007;33(4):373–388
15. Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. *Semin Thromb Hemost* 2006;32(7):651–658
16. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. *Semin Thromb Hemost* 2008;34(1):58–73
17. Bernardi E, Pesavento R, Prandoni P. Upper extremity deep venous thrombosis. *Semin Thromb Hemost* 2006;32(7):729–736
18. Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. *Semin Thromb Hemost* 2007;33(4):350–354
19. Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. *Semin Thromb Hemost* 2007;33(6):588–596
20. Michiels JJ, De Raeye H, Berneman Z, et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. *Semin Thromb Hemost* 2006;32(4 Pt 2):307–340
21. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. *Semin Thromb Hemost* 2007;33(4):313–320
22. Siegel-Axel DI, Gawaz M. Platelets and endothelial cells. *Semin Thromb Hemost* 2007;33(2):128–135
23. Stellos K, Gawaz M. Platelets and stromal cell-derived factor-1 in progenitor cell recruitment. *Semin Thromb Hemost* 2007;33(2):159–164
24. Enjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. *Semin Thromb Hemost* 2007;33:771–779
25. Middeldorp S, Levi M. Thrombophilia: an update. *Semin Thromb Hemost* 2007;33(6):563–572
26. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. *Semin Thromb Hemost* 2005;31(6):681–690
27. De Stefano V, Rossi E, Za T, Leone G. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. *Semin Thromb Hemost* 2006;32(8):767–780
28. Davie EW, Kulman JD. An overview of the structure and function of thrombin. *Semin Thromb Hemost* 2006;32(Suppl 1):3–15
29. Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. *Semin Thromb Hemost* 2008;34(1):7–25